Drug Trial Radar · NCT02513940
Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes
Last checked: Nov 19, 2026Latest source record: Aug 28, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
14
Actual
Start
May 2016
Primary completion
Oct 19, 2017
Study completion Oct 19, 2017
Sponsor
- Lead sponsor
- Indiana UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- American Heart Association; Purdue University
- First posted
- Aug 3, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- Male only, from 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Torsades de pointes (TdP) is a potentially fatal ventricular arrhythmia associated with corrected QT (QTc) interval prolongation. More than 50 commonly used drugs available on the US market may cause QTc interval prolongation and TdP. While TdP occurs more commonly in women, 33-45% of all cases of TdP have occurred in men. Older age is a risk factor for drug-induced TdP in men, possibly due to declining serum testosterone concentrations. Available evidence shows an inverse relationship between QTc intervals and serum testosterone concentrations. In addition, experimental data, including those from the investigators' laboratory, suggest that both exogenous testosterone or progesterone administration may be protective against prolongation of ventricular repolarization and TdP. Specific Aim: Establish the influence of transdermal testosterone administration and oral progesterone administration as preventive methods by which to diminish the degree of drug-induced QT interval prolongation in men 65 years of age or older. Hypothesis: Transdermal testosterone administration and oral progesterone administration both effectively attenuate drug-induced QT interval response in older men. To test this hypothesis, transdermal testosterone, oral progesterone or placebo will be administered in a 3-way crossover study to men 65 years of age or older. QTc interval response to low-dose ibutilide will be assessed. The primary endpoints will be Fridericia-corrected QT interval (QTF) response to ibutilide, in the presence and absence of testosterone, and in the presence or absence of progesterone: 1) Effect on pre-ibutilide QTF, 2) Effect on maximum post-ibutilide QTF, 3) Effect on % change in post-ibutilide QTF, and 2) Area under the QTF interval-time curves.
Conditions
- Long QT Syndrome
Interventions
TestosteroneDrug
Subjects will receive transdermal testosterone gel 1% 100 mg daily for 7 days
ProgesteroneDrug
Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
PlaceboDrug
Subjects will receive placebo transdermal gel and placebo (lactose) capsules
IbutilideDrug
Ibutilide 0.003 mg/kg administered to all subjects in all phases to moderately lengthen the QT interval
Primary outcomes
What the sponsor says the trial is designed to measure.
- Baseline (Pre-ibutilide) Individualized Rate-corrected QT Interval (QTF)Time frame: Following 7 days of testosterone, progesterone or placebo
- Maximum QTF Following Ibutilide 0.003 mg/kgTime frame: Within 8 hours following ibutilide administration
- Maximum Percent Change From Pretreatment Value in QTF Following Ibutilide 0.003 mg/kgTime frame: Within 8 hours of ibutilide administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Indiana University
Indianapolis, Indiana
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.